Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8010937 | 0.98 | ACHE (0.40) | ACHETDP1GPR84FFAR1FFAR4 | |
| SCHEMBL13445862 | 0.85 | TDP1 (0.34) | ACHETDP1MAPTMAPK1L3MBTL1 | |
| SCHEMBL27540626 | 0.82 | GPR84 (0.37) | ACHETDP1GPR84FFAR1FFAR4 | |
| SCHEMBL26923578 | 0.81 | ACHE (0.51) | ACHE | |
| SCHEMBL25185273 | 0.80 | MAPT (0.55) | GPR84FFAR1MAPT | |
| SCHEMBL10523806 | 0.80 | MAPT (0.55) | GPR84FFAR1MAPT | |
| SCHEMBL4949251 | 0.80 | MAPT (0.55) | GPR84FFAR1MAPT | |
| SCHEMBL6686954 | 0.80 | ACHE (0.46) | ACHEGPR84FFAR1FFAR4CYP4F2 | |
| SCHEMBL14685869 | 0.79 | GPR84 (0.43) | TDP1GPR84FFAR1FFAR4MAPT | |
| SCHEMBL251336 | 0.78 | NAAA (0.48) | GPR84FFAR1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9162976-B2 | Composition containing a dibenzoylmethane screening agent and a hydrophilic or water-soluble merocyanin uv-screening agent; process for photostabilizing the dibenzoylmethane screening agent | L'OREAL (FR) | 2015-10-20 | — | — | US | disclosed |
| US-20130058990-A1 | COMPOSITION CONTAINING A DIBENZOYLMETHANE SCREENING AGENT AND A HYDROPHILIC OR WATER-SOLUBLE MEROCYANIN UV-SCREENING AGENT; PROCESS FOR PHOTOSTABILIZING THE DIBENZOYLMETHANE SCREENING AGENT | L'OREAL (FR) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130058990-A1 | COMPOSITION CONTAINING A DIBENZOYLMETHANE SCREENING AGENT AND A HYDROPHILIC OR WATER-SOLUBLE MEROCYANIN UV-SCREENING AGENT; PROCESS FOR PHOTOSTABILIZING THE DIBENZOYLMETHANE SCREENING AGENT | CRYZ, MSH6, TYR | ACHE 2018/4885TDP1 3504/4885GPR84 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.